Morgan Stanley Initiates Coverage of REGENXBIO with Buy Rating
Morgan Stanley analyst Maxwell Skor has initiated coverage of REGENXBIO (RGNX) with a Buy rating and a price target of $18.
Stocks · News reference
REGENXBIO Announces $39M Settlement With Sarepta Resolving All Elevidys Patent Litigation
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — REGENXBIO Inc. (RGNX)
Filed: 2026-10-16 AccNo: 0001193125-26-423376 Size: 147 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Full Transcript: Regenxbio Q2 2026 Earnings Call
Regenxbio (NASDAQ:RGNX) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to
Mizuho Initiates Coverage On Regenxbio with Outperform Rating, Announces Price Target of $22
Mizuho analyst Graig Suvannavejh initiates coverage on Regenxbio (NASDAQ:RGNX) with a Outperform rating and announces Price Target of $22.
Sarepta Therapeutics Announces Participation in Upcoming Investor Conferences
Sarepta Therapeutics, Inc. announced that senior management will participate in two investor conferences in November 2026.
Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results
Sarepta Therapeutics has announced that it will release its financial results for the third quarter of 2026.